Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors

Bain Capital Life Sciences and GordonMD® Global Investments LP join existing investors Proceeds to support clinical development of novel fully human anti-CD19 CAR T-cell therapies for autoimmune diseases EMERYVILLE, Calif., Aug. 3, 2023 -- (Healt... Biopharmaceuticals, Venture Capital Kyverna Therapeutics
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news